DCM
STOK icon

Driehaus Capital Management’s Stoke Therapeutics STOK Stock Holding History

Driehaus Capital Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-102,489
Closed -$1.09M – 444
2023
Q2 		$1.09M Buy
+102,489
New +$1.09M 0.01% 314

Other funds holding STOK

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Driehaus Capital Management's STOK Position: Q3 2023 in Review

Driehaus Capital Management sold out of Stoke Therapeutics (STOK) in Q3 2023, closing a stake of 102,489 shares — an estimated $1.09M sold.

Driehaus Capital Management first reported a position in STOK in Q2 2023 and held it in 1 quarter. The position peaked at $1.09M in Q2 2023. 96 funds tracked by Wall St. Rank hold STOK as of Q3 2023.

  • Driehaus Capital Management reported no remaining Stoke Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Driehaus Capital Management sold 102,489 Stoke Therapeutics shares in Q3 2023, an estimated $1.09M.
  • Driehaus Capital Management first reported a position in Stoke Therapeutics in Q2 2023 and held it in 1 quarter.
  • Driehaus Capital Management's Stoke Therapeutics position peaked at $1.09M in Q2 2023.
  • 96 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2023.

Based on Driehaus Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.